ELISABETH DUPONT PASSELAIGUE,SAMUEL MIALHE,JEAN PIERRE RIEU,DIDIER JUNQUERO,KARINE VALEILLE
申请号：
FR0955504
公开号：
FR2948939B1
申请日:
2009.08.05
申请国别(地区):
FR
年份:
2013
代理人:
摘要：
The present invention concerns compounds of general formula (I) characterized in that (formula 1) wherein, in particular: &mdash；R1 represents one or more groups such as: trifluoromethyl, halogen such as F, Cl, &mdash；when n=m=1, W represents CH then Y represents oxygen, &mdash；U represents: &bull；either &mdash；(C&boxH；O)CH2NH&mdash； and is branched at position 4 of pyridazinone, then R2 represents H, &bull；or &mdash；(C&boxH；O)NH&mdash； and U is branched at positions (4), (5) or (6) of pyridazinone, then R2 represents H, &mdash；R3 represents a hydrogen or methyl and the addition salts with pharmaceutically acceptable bases and acids and the different isomers, and their mixtures in any proportion for use as SCD-1 enzyme inhibitors for the treatment of obesity, type-2 diabetes and lipid disorders.
